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Abstract 
Background: Non-small cell lung cancer (NSCLC) is the largest histological subgroup of lung cancer and has 
increased in prevalence in China over the past 5 years. The 5-year survival rate has remained at 15–20 %, with a 
median survival of 8–12 months. The tumorigenesis and progression of NSCLC is orchestrated by numerous onco-
gene and anti-oncogene mutations and insights into microRNA function have increased our understanding of the 
process. Here, we investigated the effects of miR-30b on NSCLC cell invasion and migration and explored the underly-
ing molecular mechanisms involved.
Methods: Quantitative reverse transcription PCR, wound healing assay, trans-well assays, western blotting and dual 
luciferase assays were performed to investigate the molecular mechanisms of miR-30b in NSCLC cells.
Results: MiR-30b was down-regulated and Cthrc1 up-regulated in NSCLC tissues. Both were associated with tumor 
differentiation, TNM stage and lymph node metastases. Up-regulation of miR-30b restricted A549 and Calu-3 cell inva-
sion and migration. Additionally, the expression of Cthrc1, matrix metalloproteinase-9 and matrix metalloproteinase-2 
was reduced, while metallopeptidase inhibitor-1 expression increased. Bioinformatics analysis identified Cthrc1 as a 
target of miR-30b and western blotting and luciferase reporter assays confirmed that miR-30b regulates Cthrc1 by 
directly binding to its 3′UTR. Transfection of Cthrc1 without the 3′UTR restored the miR-30b inhibiting cell invasion. 
Up-regulation of miR-30b or down-regulation of Cthrc1 had potential significance in the invasion and metastasis of 
NSCLC.
Conclusions: MiR-30b was down-regulated and Cthrc1 up-regulated in NSCLC tissues. Both of them were related to 
tumor differentiation, TNM stage and lymph node metastases. MiR-30b affected NSCLC cells invasion and migration 
by regulating Cthrc1.
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Background
Lung cancer is the most common cause of cancer-asso-
ciated deaths worldwide [1]. Non-small cell lung cancer 
(NSCLC) is the largest histological subgroup, accounting 
for 80–85 % of all lung cancers [2]. Although substantial 
progress has been made in the surgical treatment, radio-
therapy and chemotherapy of NSCLC [3–6], the 5-year 
survival rate has remained at 15–20 %, with median sur-
vival of 8–12  months [7]. The tumorigenesis and pro-
gression of NSCLC is a complex process influenced by 
multiple genetic factors, therefore early diagnosis and 
treatment is important. Preventing the tumorigenesis 
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and progression of NSCLC at the molecular level is the 
key to an effective therapeutic strategy.
Insights into the oncogenic and tumor-suppressor 
functions of microRNAs (miRNAs) have contributed to 
our understanding of NSCLC tumorigenesis and pro-
gression. miRNAs are small noncoding RNA molecules 
that regulate the expression of at least 30 % of all protein-
coding genes, influencing a variety of biological functions 
such as cell proliferation and survival, DNA repair and 
immune response [8–10]. Assorted miRNAs have been 
confirmed to play important roles in NSCLC. For exam-
ple, miR-96 and miR-21 are significantly up-regulated in 
NSCLC tissues and regulate target gene expression to 
influence NSCLC cell migration and invasion [11, 12]. 
The tumor suppressor’s miR-495, miR-486-5p and miR-
193a-3p/5p are all down-regulated in NSCLC tissues, 
contributing to the tumorigenesis and progression of the 
disease [13–15].
MiR-30b is a member of the miR-30 family, which 
plays an important regulatory role in the development of 
several cancers including breast cancer [16], malignant 
peripheral nerve sheath tumors [17], glioma [18] and 
lung cancer [19]. Collagen triple helix repeat containing 
1 (Cthrc1) has also been associated with the development 
of certain cancers, including lung cancer [20–24], there-
fore we decided to explore a possible interaction between 
miR-30b and Cthrc1 and the potential significance in the 
invasion and metastasis of NSCLC.
In our study, we detected miR-30b and Cthrc1 expres-
sion levels in NSCLC tissues, and observed alterations 
in invasion, migration and expression of some metasta-
sis associated proteins by increasing miR-30b expression 
in NSCLC cell lines. We next performed dual luciferase 
assay system and western blotting analysis on the basic 
of bioinformatics analysis using TargetScan and miRanda 
to investigated whether miR-30b regulated the expres-
sion of Cthrc1 via binding to its 3′UTR. Furthermore, co-
transfection of miR-30b and pcDNA3.1-Cthrc1 can help 
to explore whether the effect of miR-30b can be partially 
restored by Cthrc1 re-expression.
Results
MiR‑30b is down‑regulated in NSCLC tissues
Expression of miR-30b was evaluated in 63 NSCLC and 
adjacent normal tissues. We found that miR-30b expres-
sion was significantly down-regulated in NSCLC tissues 
compared to adjacent normal tissues (P < 0.05, Fig. 1a). 
Further analysis revealed that miR-30b expression in 
NSCLC tissues was associated with differentiation, TNM 
stage and lymph node metastases (P  <  0.05; Table  1; 
Fig.  1b–d). No significant differences were observed 
between miR-30b expression and gender, age or patho-
logical type (P > 0.05; Table 1).
Cthrc1 mRNA is up‑regulated in NSCLC tissues
Expression of Cthrc1 mRNA was also evaluated in 63 
NSCLC and adjacent normal tissues. Cthrc1 mRNA 
expression was significantly up-regulated in NSCLC tis-
sues (P < 0.05, Fig. 2a) and was also associated with dif-
ferentiation, TNM stage and lymph node metastases 
(P < 0.05, Table 1; Fig. 2b–d). No significant differences 
were observed between Cthrc1 mRNA expression and 
gender, age or pathological type (P > 0.05; Table 1). Pear-
son correlation analysis indicated that the expression of 
miR-30b and Cthrc1 mRNA were inversely correlated 
(R2 = 0.734, Fig. 2e).
MiR‑30b inhibits the migration and invasion of NSCLC cells
To investigate the effect of miR-30b on the migration and 
invasion of NSCLC cells, miR-30b mimic or a scrambled 
miR-30b negative control were transfected into A549 
and Calu-3 cells respectively. qRT-PCR results showed 
miR-30b expression was significantly increased in the 
miR-30b group compared with the NHBE, Scramble and 
Blank groups (P < 0.05, Fig. 3a). The wound healing assay 
and trans-well arrays for migration ability revealed that 
the migration ability of A549 and Calu-3 cells in the miR-
30b group was lower at 24  h post-wounding compared 
with both Scramble and Blank groups (P < 0.05, Fig. 3b, 
c). The cell invasion assay revealed a significant reduction 
in the average number of cells penetrating the trans-well 
membrane and matrigel in the miR-30b group (P < 0.05, 
Fig.  3d), while cells in the Scramble and Blank groups 
were not affected (P  >  0.05). The expression of Cthrc1 
and other invasion-related proteins such as TIMP-1, 
MMP-2 and MMP-9 were analyzed by western blotting. 
Cthrc1, MMP-2 and MMP-9 expression was reduced but 
TIMP-1 expression increased following transfection with 
miR-30b in A549 and Calu-3 cells (P  <  0.05, Fig.  3e, f ). 
Taken together, these findings suggest that miR-30b plays 
an important role in cell migration and invasion.
MiR‑30b down‑regulates the expression of Cthrc1 
via binding to their 3′UTR
Bioinformatics analysis by TargetScan and miRanda 
revealed a predicted binding site for miR-30b in the 
3′UTR of Cthrc1 (Fig.  4a). Furthermore, Cthrc1 expres-
sion decreased in A549 and Calu-3 cells following trans-
fection with miR-30b mimics (Fig.  4b, c). To confirm 
whether Cthrc1 is a direct target of miR-30b, we per-
formed a dual-luciferase reporter assay using luciferase-
reporter vectors containing either the wild-type or the 
mutant 3′UTR of Cthrc1. While co-transfection with 
miR-30b mimics significantly decreased the luciferase 
activity of the reporter containing wild-type 3′UTR, it 
did not suppress that of the mutant-type reporter in 
A549 and Calu-3 cells (P < 0.05, Fig. 4d, e). These findings 
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strongly suggest that miR-30b down-regulates the expres-
sion of Cthrc1 by binding to its 3′UTR.
Expression of Cthrc1 restores miR‑30b anti‑invasion 
function
We next performed western blotting and trans-well 
assays to explore whether the effect of miR-30b can be 
partially restored by Cthrc1 re-expression, which also 
further confirm that Cthrc1 is a direct target of miR-30b. 
The Cthrc1 expression in A549 and Calu-3 cells were 
lower after transfection with miR-30b mimics, and was 
higher after transfection with vector containing Cthrc1 
lacking the 3′UTR (pcDNA3.1-Cthrc1) into two cells. 
Co-transfection of miR-30b mimics and pcDNA3.1-
Cthrc1 led to increased expression of Cthrc1, and abro-
gated the Cthrc1 expression-reducing effect of miR-30b 
mimics (Fig.  5a, b). For trans-well assays, the mean 
number of cells penetrating the trans-well membrane 
and matrigel decreased after transfection with miR-30b 
mimics, but increased after transfection with pcDNA3.1-
Cthrc1 and co-transfection with pcDNA3.1-Cthrc1 and 
miR-30b mimics, abrogating the effect of miR-30b mim-
ics (Fig. 5c, d). These results further suggest that Cthrc1 
is a major target of miR-30b, and expression of Cthrc1 
restores miR-30b anti-invasion function.
Discussion
Lung cancer accounts for the foremost cause of malig-
nancy-associated death worldwide, and metastasis is one 
of the major problems. To metastasize, a cancer cell must 
acquire abilities such as the capacity to colonize new tis-
sue and evade immune surveillance, which must involve a 
broad spectrum of mechanisms. Gene expression profil-
ing experiments have uncovered many genes potentially 
implicated in cancer invasion and metastasis [25–28]. 
Matrix metalloproteinases (MMPs), a family of zinc-ion 
dependent endopeptidases comprising more than 21 sub-
types, have been widely accepted to play an important 
role on cancer invasion or metastasis [29–32]. In kinds 
of cancers, a wide spectrum of target genes are simulta-
neously regulated by multiple miRNAs, which leads to 
altered expression of invasion or metastasis-associated 
Fig. 1 Expressions of miR-30b in paired NSCLC and adjacent normal tissues. a Relative expression levels of miR-30b in paired NSCLC and adjacent 
normal tissues. There is a statistically significant difference (P < 0.05). b On the basis of differentiation, NSCLC tissues were divided into two groups 
(Well and Moderate & Poor). The down-regulation of miR-30b was notably in Moderate & Poor group (P < 0.05). c In TNM stage of tumor tissues, the 
expression of miR-30b was successively declined (P < 0.05). d On the basis of lymph node metastases, the expression of miR-30b was significantly 
lower in N0 group than N1–N3 group (P < 0.05)
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genes and influences the metastatic potential of many 
cancers [33–35]. Learning more about the cellular and 
molecular basis of miRNA-target gene axis in cancers 
will help us to understand how cancer cells disseminate 
and lead to new treatment strategies.
Accumulating evidences have suggested that altera-
tions in miRNAs expression might prove crucial in 
cancer metastasis. In NSCLC, miR-29b was found down-
regulated in high-metastatic NSCLC cells and low-
expression of miR-29b in primary NSCLC tissue and 
correlated with lymph node metastasis [36]. In vitro and 
in  vivo experiments, miR-425-5p contributes to inva-
sion and metastasis of human gastric cancer [37]. In 
melanoma cells, miR-203 was revealed to regulate mela-
noma invasive and proliferative abilities in part by target-
ing BMI1. Our research focused on miR-30b, which has 
been demonstrated that enhanced the invasive capacity 
of melanoma cells in vitro and increased their metastatic 
potential in  vivo [38]. MiR-30 was described as a “hub” 
for miRNA oncogenesis signal network in solid tumors 
[39]. Its up- or down- modulation has profound impacts 
on tumorigenesis. In our study, we found that altered 
miR-30b expression was associated with the occurrence 
of the differentiation status, TNM stage and lymph node 
metastases in NSCLC patients, which may be a hint for 
miR-30b acting as a potential tumor-suppressor contrib-
uting to the progression and metastasis of NSCLC. Nev-
ertheless, it still needs to explore the relevant mechanism 
of miR-30b in NSCLC invasion and metastasis.
Naturally, many other genes as MMP family [40] and 
Cthrc1 [24] have been demonstrated to associate with 
NSCLC invasion and metastasis during the ongoing 
researches of NSCLC. Based on bioinformatics analysis, 
we detected the Cthrc1 mRNA expression and found 
elevated expression of Cthrc1 was also associated with 
the occurrence of the differentiation status, TNM stage 
and lymph node metastases in NSCLC patients, and 
Pearson correlation analysis indicated that the expres-
sion of miR-30b and Cthrc1 mRNA were inversely cor-
related. Furthermore, we up-regulated the expression of 
miR-30b in NSCLC cell lines, and found up-regulation of 
miR-30b restricted cell migration and invasion. Western 
blotting array was used to analyze the expression of inva-
sion-related proteins and the results showed that Cthrc1, 
MMP-9 and MMP-2 were declined but TIMP-1 was 
increased following transfection with miR-30b in A549 
and Calu-3 cells, which is a hint that miR-30b plays an 
important role in cell migration and invasion of NSCLC. 
Owing to the role of miRNA was realized by targeting 
the gene expression, the related mechanism need to be 
Table 1 miR-30b and Cthrc1 mRNA expression levels were associated with clinicopathological features of NSCLC patients
SCC squamous cell carcinoma, AC adenocarcinoma
* Indicated statistical significance (P < 0.05)
Clinicopathological factor n miR‑30b(2−ΔΔCt) Cthrc1 mRNA(2−ΔΔCt)
Median ± SD P Media ± SD P
Gender
 Male 38 0.2847 ± 0.1138 0.720 2.2714 ± 0.3568 0.707
 Female 24 0.2960 ± 0.1307 2.2371 ± 0.3359
Age (years)
 ≥60 35 0.3081 ± 0.1324 0.156 2.222 ± 0.3971 0.345
 <60 27 0.2644 ± 0.0979 2.305 ± 0.2672
Histology
 SCC 21 0.3033 ± 0.0992 0.508 2.2548 ± 0.2960 0.957
 AC 41 0.2818 ± 0.1295 2.2599 ± 0.3732
Differentiation
 Well 21 0.3455 ± 0.1533 0.007* 2.1035 ± 0.4324 0.011*
 Moderate & Poor 41 0.2602 ± 0.0870 2.3374 ± 0.2656
TNM
 I 25 0.3540 ± 0.1327 0.000* 2.1010 ± 0.3440 0.005*
 II 23 0.2663 ± 0.0927 2.3126 ± 0.2796
 III 14 0.2107 ± 0.0677 2.4494 ± 0.3470
Lymphnode metastasis
 N0 47 0.3129 ± 0.1234 0.005* 2.1952 ± 0.3290 0.010*
 N1–N3 15 0.2147 ± 0.0670 2.4555 ± 0.3352
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further analyzed. Bioinformatics analysis revealed that 
one target of miR-30b was Cthrc1. The 3′UTR region of 
Cthrc1 was amplified from human genomic DNA and 
inserted into the pmirGLO vector to construct a lucif-
erase reporter plasmid. After transfection into A549 and 
Calu-3 cells, western blotting and luciferase reporter 
assays were performed and the results demonstrated 
that miR-30b regulated Cthrc1 by directly binding to its 
3′UTR. Moreover, western blotting and trans-well assays 
further suggest that Cthrc1 is a major target of miR-30b, 
and expression of Cthrc1 restores miR-30b anti-invasion 
function.
Conclusions
MiR-30b was down-regulated and Cthrc1 up-regulated 
in NSCLC tissues. Both of them were related to tumor 
differentiation, TNM stage and lymph node metasta-
ses. We also provided evidence demonstrating miR-30b 
affected NSCLC cells invasion and migration by regulat-
ing Cthrc1 expression. In the future, the miR-30b-Cthrc1 
pathway could be exploited in a therapeutic approach for 
the treatment of NSCLC.
Methods
Patients and tissue specimens
Paired tumorous and adjacent normal tissues (≥3  cm 
away from tumor) were obtained from 63 NSCLC 
patients. All specimens were clinically and histologically 
diagnosed at the First Affiliated Hospital of Zhengzhou 
University between 2012 and 2014. The tumorous and 
adjacent normal tissues were snap-frozen in liquid nitro-
gen immediately after resection and stored at −80  °C 
until RNA extraction. This study was approved by the 
Ethics Committee of Zhengzhou University and written 
consent was obtained from all patients.
Cell culture
Normal human bronchial epithelial cells (NHBE) and 
two human lung cancer cell lines (A549 and Calu-3) were 
used in this study (American Type Culture Collection, 
Manassas, VA, USA). NHBE, A549 and Calu-3 cells were 
cultured in Dulbecco’s modified Eagle medium (DMEM; 
Gibco, CA, USA) containing 10  % fetal bovine serum 
(FBS; Gibco), 100 U/mL penicillin and 100 μg/mL strep-
tomycin at 37 °C with a humidified 5 % CO2 atmosphere.
Fig. 2 Expressions of Cthrc1 mRNA in paired NSCLC and adjacent normal tissues. a Relative expression levels of Cthrc1 mRNA in paired NSCLC and 
adjacent normal tissues. There is a statistically significant difference (P < 0.05). b On the basis of differentiation, NSCLC tissues were divided into two 
groups (Well and Moderate & Poor). The up-regulation of Cthrc1 was notably in Moderate & Poor group (P < 0.05). c In TNM stage of tumor tissues, 
the expression of Cthrc1 was successively increased (P < 0.05). d On the basis of lymph node metastases, the expression of Cthrc1 was significantly 
higher in N0 group than N1–N3 group (P < 0.05). e The expressions of miR-30b and Cthrc1 mRNA were negatively correlated (R2 = 0.734, P < 0.05)
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RNA extraction and quantitative real‑time PCR
Quantitative real-time PCR (qRT-PCR) arrays were used 
to detect the relative levels of miR-30b and Cthrc1 mRNA 
in 63 paired tumorous and adjacent normal tissues. Total 
RNA was extracted from those frozen tissue samples 
containing >80  % NSCLC cells. An RNA Extraction Kit 
(Qiagen) was used to extract total RNA according to 
the manufacturer’s instructions and RNA quality was 
Fig. 3 MiR-30b inhibits NSCLC cells migration and invasion. a After transfection of miR-30b mimics or Scramble, qRT-PCR results showed miR-30b 
expression was significantly increased in miR-30b group compared with NHBE group, Scramble and Blank groups (P < 0.05). b Wound healing 
assays were used to assess the migration ability of A549 and Calu-3 cells after transfection. miR-30b group showed a lower cell density at 24 h post-
wounding compared with both Scramble and Blank groups (P < 0.05). c Transwell migration assays were used to assess the migration ability of A549 
and Calu-3 cells after transfection. The numbers of A549 and Calu-3 cells in the miR-30b group passing through membrane were significantly lower 
compared with those from the Scramble and Blank groups (P < 0.05). d Transwell invasion assays were used to assess the invasion n ability of A549 
and Calu-3 cells after transfection. The numbers of A549 and Calu-3 cells in the miR-30b group passing through the membrane and matrigel were 
significantly lower compared with those from the Scramble and Blank groups (P < 0.05).e, f Western blotting was used to analyze the expression 
of Cthrc1 and some other invasion-related proteins such as Cthrc1, TIMP-1, MMP-2 and MMP-9 in A549 and Calu-3 cells. The results showed that 
Cthrc1, MMP-2 and MMP-9 were declined but TIMP-1 was increased following transfection with miR-30b in A549 and Calu-3 cells (P < 0.05). miR-30b 
cells transfected with miR-30b mimics; Scramble cells transfected with scrambled miR-30b negative control; Blank cells with non-transfected
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confirmed using a NanoDrop 1000 Spectrophotometer 
(Thermo Fisher Scientific, Wilmington, DE, USA). RNA 
purity was determined by an OD260/280 value of at least 
1.8. For miR-30b expression, cDNA was obtained using 
the miScript Reverse Transcription Kit (Qiagen) with 
specific miRNA primers (Applied Biosystems). MiR-30b 
expression was detected using the TaqMan human 
microRNA assay kit (Qiagen). U6 snRNA was used as an 
endogenous control to normalize the data. For Cthrc1 
mRNA expression, RNA was reverse-transcribed with 
random primers using an ABI® Reverse Transcription 
Kit (Applied Biosystems) and qRT-PCR were performed 
Fig. 4 Cthrc1 was identified as a target of miR-30b in A549 and Calu-3 cells. a Bioinformatics analysis showed the putative binding sequence 
between miR-30b and Cthrc1 3′UTR. b, c Western blotting analysis of Cthrc1 expression in transfected A549 and Calu-3 cells. GAPDH was used as 
an endogenous control. d, e Luciferase activity determined 48 h after transfection in A549 and Calu-3 cells. In cells co-transfected with mutant-type 
3′UTR of Cthrc1, no difference was found between the relative luciferase activity of cells co-transfected with miR-30b and that of the Scramble 
group. However, in cells co-transfected with wild-type 3′UTR, the relative luciferase activity of the cells co-transfected with miR-30b was significantly 
lower compared with the Scramble group. miR-30b cells transfected with miR-30b mimics; Scramble cells transfected with scrambled miR-30b nega-
tive control; Blank non-transfected cells
Fig. 5 Expression of Cthrc1 restores miR-30b anti-invasion function. a, b Western blotting arrays results the Cthrc1 expression of A549 and Calu-3 
cells was lower after transfection with miR-30b mimics, and was higher after transfection with miR-30b inhibitor. However, Co-transfection of miR-
30b mimics and pcDNA3.1-Cthrc1 led to increased expression of Cthrc1, and abrogated the Cthrc1 expression-reducing effect of miR-30b mimics. c, 
d Trans-well arrays results the mean number of cells penetrating the trans-well membrane and matrigel decreased increased after transfection with 
miR-30b mimics, but increased after transfection with pcDNA3.1-Cthrc1 and co-transfection with pcDNA3.1-Cthrc1 and miR-30b mimics, abrogat-
ing the effect of miR-30b mimics
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using ABI Power SYBR® Green I PCR Master Mix 
(Applied Biosystems) on the ABI 7500 Fast (Applied Bio-
systems) with glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) as an internal control. Data were analyzed 
using ABI Prism7500 SDS Software (Applied Biosys-
tems, USA). All protocols were performed according to 
the manufacturers’ instructions. The comparative cycle 
threshold (CT) (2−ΔΔCT) method was used to calculate 
the relative expression of miR-30b and Cthrc1 mRNA.
Western blotting
Total protein from each group was extracted and the 
protein concentration was measured using the Bradford 
DC protein assay (Bio-Rad, Hercules, CA, USA). 25 μg 
protein from each sample was separated using SDS–
polyacrylamide gel electrophoresis (10  %) and blotted 
onto polyvinylidene difluoride (PVDF) filter membranes 
(Whatman). The membranes were blocked in 5  % skim 
milk for 1 h, washed four times with Tris-buffered saline 
containing Tween 20 (TBST) at room temperature and 
then incubated overnight at 4  °C with diluted primary 
antibodies (rabbit anti-human Cthrc1/TIMP-1/MMP-2/
MMP-9 antibody, 1:500, Santa Cruz). Following extensive 
washing with TBST, membranes were incubated with 
secondary antibodies at room temperature for 1 h (goat 
anti-rabbit IgG, 1:1000, Santa Cruz). After four 15  min 
washes with TBST at room temperature, immunoreac-
tivity was visualized by enhanced chemiluminescence. 
GAPDH expression (Santa Cruz Biotechnology) served 
as an endogenous reference.
Cell transfection
For transfection, A549 and Calu-3 cells were seeded into 
6-well plates at a density of 5 × 104 cells/well. Transient 
transfection was performed at approximately 80  % con-
fluence using Lipofectamine™2000 (Invitrogen, Carlsbad, 
CA, USA) according to the manufacturer’s instructions. 
50 nM GMR-miRTM was mixed with a miR-30b mimic 
or scrambled miR-30b negative control (Shanghai 
GenePharma) in 1  µl of Lipofectamine reagent. After 
24  h, qRT-PCR was used to evaluate transfection effi-
ciencies. According to the requirements of the differ-
ent experiments, A549 and Calu-3 cells were separated 
into three respective groups; Blank: untransfected cells, 
Scrambled: cells transfected with scrambled miR-30b 
negative control, and miR-30b: cells transfected with 
miR-30b mimics.
Wound healing assay
Cell migration was analyzed using the wound healing 
assay. At 90  % density in 6-well plates, a sterile 200 μL 
pipette tip was used to scratch a straight line through the 
A549 and Calu 3 cell layers and the culture medium was 
changed. Cells were photographed 24 h after scratching. 
Assays were repeated three times for each clone.
Trans‑well assay
For cell invasion assay, trans-well filters (Costar) were 
coated with matrigel (3.9 μg/μl, 60–80 μl) on the upper 
surface of a polycarbonic membrane (6.5  mm diameter, 
8  μm pore size). After 24  h post-transfection and then 
6  h serum starvation, A549 and Calu-3 cells (2  ×  105) 
were resuspended in 200  μl of serum-free medium in 
the upper chambers, and while 500 μl media containing 
10 % FBS (as a chemoattractant) was added to the bottom 
chamber. After incubating for 8 h at 37  °C in a humidi-
fied incubator with 5 % CO2, cells in the upper chamber 
were carefully removed with a cotton swab. Cells that had 
migrated to the basal side of the membrane were fixed 
with methanol, stained with hematoxylin, mounted and 
dried at 80  °C for 30  min. We randomly selected three 
visual fields and counted and recorded the number of 
cells invading the matrigel with an inverted microscope 
at 200× magnification. Each test was performed in trip-
licate. With the similar principle and approach, we used 
trans-well filters (Costar) with uncoated matrigel on 
the upper surface of a polycarbonic membrane (6.5 mm 
diameter, 8 μm pore size) for cell migration assay.
Vector construction and the dual‑luciferase reporter assay
The 3′UTR region of Cthrc1 was amplified from human 
genomic DNA and inserted into the pmirGLO vector 
(Promega, Madison, WI, USA) with XhoI and SalI at the 
3′ end of the luciferase gene to construct the luciferase 
reporter plasmids pmirGLO-Cthrc1-Wt and pmirGLO-
Cthrc1-Wt. Site-directed mutagenesis of the miR-30b 
target site in the Cthrc1 3′UTR was performed using a 
QuikChange Site-Directed Mutagenesis kit (Promega) 
and pmirGLO- Cthrc1-Wt as the template. For the 
luciferase reporter assay, A549 and Calu-3 cells were 
seeded into 96-well plates and transfected with 50  nM 
of miR-30b mimic or Scrambled and 200 ng of luciferase 
reporter plasmid (pmirGLO-Cthrc1-Wt/pmirGLO-
Cthrc1-Mut) using Lipofectamine™2000 (Invitrogen). 
48  h after transfection, cells were harvested and lucif-
erase activity was measured with a Dual-Luciferase 
assay kit (Promega) according to the manufacturer’s 
instructions.
Statistical analysis
All analyses were performed with SPSS 17.0 software. 
Normal distribution was confirmed by the normal dis-
tribution test and data were expressed as mean ± stand-
ard deviation. Significance between groups was analyzed 
using the student’s t test and one-way analysis of vari-
ance (ANOVA). Pearson correlation analysis was used to 
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analyze correlation between different variable elements. 
P < 0.05 was considered statistically significant.
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